On Wednesday 30 November the Medicines Evaluation Board (MEB) organised an informative meeting in Utrecht about the implications of the new pharmacovigilance legislation. This meeting was primarily targeted at marketing authorisation holders.
The new legislation comes into effect on 1 July 2012 and also has implications for pharmaceutical companies. Because of the broad scope of [...]
On wednesday 30 November the MEB will organize an informative meeting on the implications of the new legislation for marketing authorisation holders. This meeting will be in Dutch. Among the topics will be PSURs, patient reports and additional monitoring, implementation and transparency. Visit our website for more information and a
On 3 November 2011, CBG-MEB organised together with the Association Pharmacy & Law (VF&R) a conference “The consequences of the new pharmacovigilance legislation for the Netherlands: what is new?”. Next to VF&R and CBG-MEB, CCMO, IGZ, patient representatives, industry, Lareb and the Ministry of Health, Welfare and Sport contributed to this meeting.
It was a successful [...]
Categories
